AR011231A1 - Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejorador - Google Patents

Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejorador

Info

Publication number
AR011231A1
AR011231A1 ARP980105979A ARP980105979A AR011231A1 AR 011231 A1 AR011231 A1 AR 011231A1 AR P980105979 A ARP980105979 A AR P980105979A AR P980105979 A ARP980105979 A AR P980105979A AR 011231 A1 AR011231 A1 AR 011231A1
Authority
AR
Argentina
Prior art keywords
compounds
improver
hyperuricemia
insulin sensitivity
administration
Prior art date
Application number
ARP980105979A
Other languages
English (en)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of AR011231A1 publication Critical patent/AR011231A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

El uso de un mejorador de sensibilidad a la insulina que se destina para la fabricacion de un medicamento para el tratamiento o prevencion de lahiperuricemia en un mamífero; y composicion farmacéutica que comprende dicho mejorador. El tratamiento inicial de los síntomas de la hiperuricemia,particularmente la gota, puede ser mediante la administracion de un agente analgésico, tal como colchicina, y/o antiinflamatorio analgésico tal comoindometacina. Es una práctica comun el tratar el problema de plazo más largo de la hiperuricemia mediante el control de la dieta, por ejemplo limitando elconsumo de alcohol o controlando el consumo de calorías. Sin embargo, si este tratamiento dietético no funciona lo suficientemente bien,la enfermedadpuede ser tratada mediante la administracion de fármacos, por ejemplo mediante la adminitracion profiláctica de un agente analgésico, tal como colchicina, opor medio de un estimulador de excrecion de ácido urico, tal como probenecid,sulfinpirazona, cetofenil-butazona, bucoloma o benzbromarona, o un inhibidorde síntesis de ácido urico tal como alopurinol. En particular, los mejoradores de sensibilidad a la insulina empleados se seleccionan preferiblemente delgrupo que consistede compuestos de tiazolidinodiona, compuestos de iminotiazolidinona, compuestos de diiminotiazolidina, compuestos detioxotiazolidinona, compuestos de iminotriazol, compuestos de oxazolidinodiona, compuestos de isoxazolidinodiona y compuestos oxadiazolidinodiona,preferiblemente los compuestos de tiazolidinodiona. Se incluyen también las sales farmacéuticamente aceptables de estos compuestos.
ARP980105979A 1997-11-25 1998-11-25 Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejorador AR011231A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32318297 1997-11-25

Publications (1)

Publication Number Publication Date
AR011231A1 true AR011231A1 (es) 2000-08-02

Family

ID=18151987

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105979A AR011231A1 (es) 1997-11-25 1998-11-25 Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejorador

Country Status (23)

Country Link
US (1) US6353009B1 (es)
EP (1) EP0919232B1 (es)
KR (1) KR19990045531A (es)
AR (1) AR011231A1 (es)
AT (1) ATE278400T1 (es)
AU (1) AU744653B2 (es)
BR (1) BR9805012A (es)
CA (1) CA2254394C (es)
CZ (1) CZ378898A3 (es)
DE (2) DE69826811T4 (es)
ES (1) ES2230657T3 (es)
HK (1) HK1020259A1 (es)
HU (2) HUP9902721A2 (es)
ID (1) ID21332A (es)
IL (1) IL127219A (es)
NO (1) NO985484L (es)
NZ (1) NZ332895A (es)
PL (1) PL329893A1 (es)
RU (1) RU2190425C2 (es)
SA (1) SA99191266A (es)
TR (1) TR199802441A2 (es)
TW (1) TW592697B (es)
ZA (1) ZA9810788B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
AU3195700A (en) * 1999-05-27 2000-12-18 Tanabe Seiyaku Co., Ltd. Remedies for kidney diseases and method for screening the same
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
AU2001294673A1 (en) * 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
CN101613321A (zh) * 2002-03-05 2009-12-30 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US20050025823A1 (en) * 2003-07-29 2005-02-03 Fong Andy A.T. Methods of use of herbal compositions
JP2005092923A (ja) * 2003-09-12 2005-04-07 Renesas Technology Corp 半導体記憶装置
EP1778261A4 (en) 2004-07-21 2010-08-11 Univ Florida COMPOSITIONS AND METHODS FOR TREATMENT AND DIAGNOSIS OF INSULIN RESISTANCE
CA2617161A1 (en) * 2005-07-21 2007-02-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
MX2009010790A (es) * 2007-04-05 2009-10-29 Daiichi Sankyo Co Ltd Derivados de heteroarilo biciclico fusionados.
RU2480463C1 (ru) 2009-03-05 2013-04-27 Дайити Санкио Компани, Лимитед Пиридилокси производные, полезные в качестве активатора/модулятора гамма-рецептора, активируемого пролифератором пероксисом (ppar) гамма
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) * 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
RU2014134845A (ru) * 2012-01-27 2016-03-20 Тейдзин Фарма Лимитед Терапевтическое средство против диабета
CA2912216A1 (en) 2013-05-22 2014-11-27 Telomere Diagnostics, Inc. Measures of short telomere abundance
US20190152967A1 (en) * 2016-04-04 2019-05-23 The Schepens Eye Research Institute, Inc. Peroxisome proliferator-activated receptor gamma selective agonists for inhibition of retinal pigment epithelium degeneration or geographic atrophy

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS58118577A (ja) 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
WO1986007056A1 (en) * 1985-05-21 1986-12-04 Pfizer Inc. Hypoglycemic thiazolidinediones
ZA873745B (en) 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
US4873255A (en) 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
FI91869C (fi) 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
EP0295828A1 (en) 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
EP0842925A1 (en) 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US5194443A (en) 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5260445A (en) 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5232925A (en) 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5120754A (en) 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008650A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
US4897405A (en) 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919434D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469383A (ja) 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd 置換チアゾリジン誘導体
GB9017218D0 (en) 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
WO1994001488A1 (en) * 1992-07-02 1994-01-20 Novo Nordisk A/S POLYMERIZATION OF LIGNIN AT ALKALINE pH
GB9223059D0 (en) 1992-11-04 1992-12-16 Bamford Excavators Ltd Intercooler apparatus
JP2845743B2 (ja) 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
JPH06211657A (ja) 1993-01-21 1994-08-02 Mochida Pharmaceut Co Ltd 尿酸排泄剤
HU228260B1 (en) 1993-09-15 2013-02-28 Daiichi Sankyo Company Pharmaceutical compositions to treat impaired glucose tolerance
CA2157032C (en) * 1993-12-27 1999-09-28 Hisashi Shinkai Isoxazolidinedione derivative and use thereof
RU2151145C1 (ru) * 1994-04-11 2000-06-20 Санкио Компани Лимитед Промежуточное соединение для получения гетероциклических соединений, обладающих антидиабетической активностью
US5703096A (en) 1994-10-07 1997-12-30 Sankyo Company, Limited Oxime derivatives, their preparation and their therapeutic use
IL118474A (en) 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus

Also Published As

Publication number Publication date
ES2230657T3 (es) 2005-05-01
HK1020259A1 (en) 2000-04-07
TR199802441A3 (tr) 1999-10-21
HU9802721D0 (en) 1999-01-28
TW592697B (en) 2004-06-21
ZA9810788B (en) 1999-05-25
ID21332A (id) 1999-05-27
NZ332895A (en) 2001-04-27
TR199802441A2 (xx) 1999-10-21
AU9410298A (en) 1999-06-17
DE69826811T2 (de) 2005-06-16
KR19990045531A (ko) 1999-06-25
SA99191266A (ar) 2005-12-03
CZ378898A3 (cs) 1999-07-14
AU744653B2 (en) 2002-02-28
PL329893A1 (en) 1999-06-07
IL127219A (en) 2001-08-08
ATE278400T1 (de) 2004-10-15
DE69826811T4 (de) 2006-09-21
NO985484D0 (no) 1998-11-24
HUP9902721A2 (hu) 1999-12-28
RU2190425C2 (ru) 2002-10-10
EP0919232B1 (en) 2004-10-06
BR9805012A (pt) 2000-03-21
HUP9802721A1 (hu) 2000-03-28
DE69826811D1 (de) 2004-11-11
EP0919232A1 (en) 1999-06-02
CA2254394A1 (en) 1999-05-25
IL127219A0 (en) 1999-09-22
NO985484L (no) 1999-05-26
CA2254394C (en) 2009-11-17
US6353009B1 (en) 2002-03-05

Similar Documents

Publication Publication Date Title
AR011231A1 (es) Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejorador
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
NO981628D0 (no) (Metylsulfonyl)fenyl-2-(5H)-furanoner som cox-2 inhibitorer
ATE397602T1 (de) 9-(piperazinylalkyl)carbazole als bax-modulatoren
CU20000176A7 (es) Composiciones de celecoxib
BR0210267A (pt) Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
BRPI0317463B8 (pt) composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
ES2099186T3 (es) Nuevos inhibidores de elastasa activos por via oral.
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
HUP0402506A2 (hu) FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére
BR9809968A (pt) Aplicação de derivados tiazolidinadiona no tratamento da pcos e diabetes gestacional
IT1245891B (it) Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali.
YU50401A (sh) Farmaceutski sastav koji sadrži inhibitore protonske pumpe
DK599789A (da) 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler
Armour et al. Inhibition of bone resorption in vitro and prevention of ovariectomy‐induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026)
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
BR9910678A (pt) Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto
ATE253571T1 (de) 2-heterozyklisch-5-hydroxy-1,3-pyrimidinen verwendbar als entzündungswidrigesmittel
US20170029388A1 (en) Treatment of Neurodegenerative Diseases with Asparagine Endopeptidase (AEP) Inhibitors and Compositions Related Thereto
HUP9801022A2 (hu) Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására
DK0952159T3 (da) Anvendelse af phenylhydrazonderivater som antiinflammatoriske eller analgetiske midler
US9839645B2 (en) Agents for killing HIV-1-infected cells and application thereof
SE9902937D0 (sv) Pharmaceutical compositions
BR0312943A (pt) Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib

Legal Events

Date Code Title Description
FB Suspension of granting procedure